Skip to main content

Table 2 Adverse events (worst grade; ≥ 2pts) possibly, probably or definitely related to the study regimen (N = 30)

From: Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

Type Any Grade Grade 3 Grade 4
No. patients % No. Pts. % No. Pts. %
Skin
 Pruritus 19 63 2 7 0 0
 Rash maculopapular 14 47 6 20 0 0
Gastrointestinal
 Diarrhea/Colitis 15 50 3 10 0 0
 Nausea 16 53 1 3 0 0
 Vomiting 9 30 1 3 0 0
Hepatic
 ALT 22 73 6 20 0 0
 AST 28 93 5 17 1 3
Endocrine
 Hypothyroidism 8 27 0 0 0 0
 Hyperthyroidism 3 10 0 0 0 0
 Adrenal insufficiency 10 33 3 10 0 0
 Hypophysitis 2 7 2 7 0 0
 Lipase increased 9 30 3 10 0 0
Hematologic
 Neutropenia 21 70 2 7 0 0
 Thrombocytopenia 20 67 0 0 0 0
Other
 Fever 17 57 0 0 0 0
 Fatigue 27 90 16 53 0 0
 CPK increased 19 63 2 7 0 0
 Creatinine increased 6 20 2 7 0 0